Breakthrough Clinical Advances to be Unveiled by Ascentage Pharma at AACR 2024

Ascentage Pharma, a leading biopharmaceutical company, has announced its plans to present three groundbreaking clinical advancements at the American Association for Cancer Research (AACR) Annual Meeting in 2024. This highly anticipated event will showcase Ascentage Pharma' innovative drug candidates, including Olverembatinib, APG-115, APG-2449, and APG-5918, in their respective areas of therapeutic focus. With the abstracts already published on the AACR website, these advancements hold immense promise for the future of cancer treatment.

Olverembatinib's Superior Antitumor Activity in SDH-Deficient Neoplasms:

One of the key highlights of Yasheng's clinical research is the novel multikinase inhibitor Olverembatinib, which has demonstrated remarkable antitumor activity in succinate dehydrogenase (SDH)-deficient neoplasms. The results of preclinical studies show that Olverembatinib outperforms other tyrosine kinase inhibitors in tumor cells with SDH deficiencies. Mechanistic studies have revealed that Olverembatinib exerts its antitumor effects by modulating multiple signaling pathways associated with SDH-deficient tumors, such as hypoxia, angiogenesis, cell proliferation, and apoptosis. These findings provide a solid scientific foundation for the potential clinical application of Olverembatinib in this challenging subset of tumors.

Synergistic Inhibition of Tumor Growth in Prostate Cancer Models:

Ascentage Pharma' research also highlights the synergistic effects of the embryonic ectoderm development (EED) inhibitor APG-5918 and the MDM2 inhibitor alrizomadlin in preclinical models of prostate cancer (PCa). Through their regulation of DNA methylation, cell cycle progression, and apoptosis-related pathways, the combination of APG-5918 and APG-115 has demonstrated enhanced antitumor activity. These findings lay the groundwork for the clinical development of a combination therapy involving APG-5918 and APG-115 in the treatment of prostate cancer.

APG-2449 Enhances Antitumor Efficacy in Epithelial Ovarian Cancer:

Ascentage Pharma' research has also revealed the potential of APG-2449, a novel focal adhesion kinase (FAK) inhibitor, in the treatment of epithelial ovarian cancer (EOC). APG-2449 has been shown to inhibit tumor cell migration and synergistically enhance the antitumor efficacy of PEGylated liposome doxorubicin (PLD) in EOC cells. These findings provide a promising direction for the further clinical development of APG-2449 in combination with PLD for the treatment of ovarian cancer.

Ascentage Pharma' upcoming presentation at the AACR 2024 Annual Meeting marks a significant milestone in cancer research. The groundbreaking clinical advancements in Olverembatinib, APG-115, APG-2449, and APG-5918 hold immense potential for improving patient outcomes in various cancer types. By unveiling these novel therapeutic candidates, Ascentage Pharma continues to contribute to the advancement of cancer treatment and brings hope to patients worldwide. The AACR Annual Meeting will provide a platform for researchers and industry professionals to engage in meaningful discussions and collaborations, ultimately driving the progress towards more effective cancer therapies.